Abstract

Background and Objectives: Diabetes Mellitus is considered as an independent risk factor for cognitive impairment and dementia. In this study, we evaluated the neurocognitive disorders by the MMSE and MoCA examination among the type 2 diabetic patients with cognitive impairment. Patients and Methods: This prospective study enrolled 102 patients over 45 years old who having cognitive impairment. The mild neurocognitive and major neurocognitive disorders were ruled out by using the the Diagnostic and Statistical Manual of Mental Disorders (DSM–5). All type 2 diabetic patients were underwentneurocognitive disorders by using both the MMSE and MoCA tests. Results: The mean crude score of the MMSE was 25,72± 4,10 and MoCA was 20,73± 5,08, the average point score of male was higher than female group. The prevalence of mild neurocognitive disorders was 41,18% and major neurocognitive disorder was 58,82% (p> 0,247). The score of the MMSE in the Mild neurocognitive disorder group higher than in major cognitive disorder group (27,83±1,87 vs 24,23±4,56 , p< 0,0001). The score of the MoCA in the mild neurocognitive disorder group was higher than in major neurocognitive disorder group    (24,86±2,62 vs 17,83±4,33, p<0,0001). MoCA test have specificity and sensitivity higher than MMSE test for screening neurocognitive disorder [AUC ROC   92,6%  (Se=80,0%,  Sp=92,9  %)  vs 75,3% (Se=100,00%, Sp= 38,8%)]. The new cut off for MoCA was 21 and MMSE was 23 for the type 2 diabetic patients with neurocognitive disorders. Conclusions: The score of MoCA and MMSE in the type 2 diabetic patients with neurocognitive disorders were lower than in the diabetic patients without them. The specificity and sensitivity of MoCA test were higher than MMSE test for screening neurocognitive disorders.